Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is that....is that green???
I agree! Without commercial development plan, we will sit steady down at these levels.
Gonna take some news to get this thing firing again... Wake up MCUJ!
I agree! Have been in this and watching this for a few years.
It'd be nice to see some volume...
This one is definitely one with promise. Have to be patient with her though.
I bought this stock a couple years ago at .08, but not heavily. I've been reading about it now for awhile and it looks promising. But couldn't it take quite a while for this thing to finally pop? I'm new to the stock market but I'm thinking of buying while this one is at .03. Any advice for a newbie?
MCUJ - Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT
Medicure (QB) (USOTC:MCUJ)
Today : Thursday 10 May 2012
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce the commencement of enrollment in SAVI-PCI ("Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention") a prospective, multicenter, randomized clinical trial of its commercial product, AGGRASTAT® (tirofiban HCl), in the United States. Initiation of the study marks a significant milestone in the Company's evaluation of the High-Dose Bolus (HDB) plus short infusion regimen of AGGRASTAT.
The first sites initiated in the SAVI-PCI (pronounced savvy) study are the Centennial Heart and Vascular Center, Nashville, TN and the Levinson Heart Hospital on the Chippenham Campus of CJW Medical Center, Richmond, VA. Both facilities are part of the cardiovascular clinical site network of the Sarah Cannon Research Institute (SCRI), Nashville, TN.
"We are pleased to see the commencement of enrollment at two of our leading facilities and we look forward to seeing all sites enrolling in the near future, " commented Steven V. Manoukian, MD, Principal Investigator for the study and Director of Cardiovascular Research at the Sarah Cannon Research Institute (SCRI). "The investigational tirofiban dosing regimen being evaluated in this study has potential to provide the efficacy for which this class of therapy is known but with lower bleeding risk, more efficient throughput and lower cost."
The SAVI-PCI study will enroll approximately 600 patients undergoing percutaneous coronary intervention (PCI) at sites across the United States. The study is designed to evaluate whether patients receiving the investigational, HDB regimen of AGGRASTAT (25 mcg/kg bolus over 3 minutes) followed by a shortened, 1 to 2 hour infusion of 0.15 mcg/kg/min will have outcomes that are similar, or "non-inferior," to patients receiving a 12 to 18 hour infusion of Integrilin® (eptifibatide) (Merck & Co., Inc.) at its FDA approved dosing regimen. The primary objective of SAVI-PCI is to demonstrate AGGRASTAT is non-inferior to Integrilin with respect to the composite endpoint of death, PCI-related myocardial infarction, urgent target vessel revascularization, or major bleeding within 48 hours following PCI or hospital discharge. The secondary objectives of this study include the assessment of safety as measured by the incidence of major bleeding.
Both AGGRASTAT and Integrilin are reversible, small molecule glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors that have been shown in clinical trials to reduce the combined incidence of death and myocardial infarction in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI) undergoing cardiac catheterization when compared to heparin. These agents work by preventing the aggregation of platelets and formation of blood clots which can result in a partial or complete blockage of the coronary artery if left untreated. Bleeding is a common adverse reaction associated with the use of GP IIb/IIIa inhibitors due to their unique ability to prevent blood clots. A patient's risk of bleeding is an important factor when determining an optimal treatment approach and, in some cases, complicates or limits the use of these agents. With the SAVI-PCI study, the investigators will explore whether AGGRASTAT HDB plus a shortened infusion can reduce the risk of bleeding while maintaining comparable ischemic protection relative to the currently practiced 12 to 18 hour infusion of Integrilin. Other studies have indicated that shortening the infusion duration of GP IIb/IIIa inhibitors can potentially lead to a reduction in bleeding complications for patients undergoing PCI. It is important to note that bleeding complications have been linked to increased rates of other major complications and mortality, as well as increased overall cost of care. A goal of the SAVI-PCI study is to further optimize the safety, efficacy and efficiency of treatment used in the setting of PCI.
The study is sponsored by Medicure's subsidiary, Medicure International, Inc. in partnership with SCRI and GVI Clinical Development Solutions (CDS). SCRI is one of the largest, community-based research programs in the United States, conducting cardiology and oncology clinical trials through its affiliation with a network of hundreds of physicians. CDS is a full-service Contract Research Organization with extensive clinical development experience across a multitude of therapeutic areas, and a track record of delivering quality data on time at competitive costs.
About Aggrastat
AGGRASTAT (tirofiban HCl), in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure. AGGRASTAT has been studied in a setting that included aspirin and heparin.
Bleeding is the most common complication encountered during therapy with AGGRASTAT. Administration of AGGRASTAT is associated with an increase in bleeding events classified as both major and minor bleeding events by criteria developed by the Thrombolysis in Myocardial Infarction Study group (TIMI). Most major bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Fatal bleedings have been reported. AGGRASTAT should be used with caution in patients with platelet count less than 150,000/mm3, in patients with hemorrhagic retinopathy, and in chronic hemodialysis patients. Because AGGRASTAT inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis. The safety of AGGRASTAT when used in combination with thrombolytic agents has not been established. During therapy with AGGRASTAT, patients should be monitored for potential bleeding. When bleeding cannot be controlled with pressure, infusion of AGGRASTAT and heparin should be discontinued.
AGGRASTAT is a parenteral non-peptide; reversible GP IIb/IIIa receptor antagonist that is marketed in the United States by Medicure Pharma, Inc. Medicure does not promote unapproved use of AGGRASTAT. Please see the AGGRASTAT Prescribing Information for approved indications, dosage regimens and safety related information. The AGGRASTAT dosing regimen and the treatment setting studied in the SAVI-PCI study have not been approved by the FDA.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and commercialization of novel small molecule therapeutics. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for acute coronary syndromes in the United States, where it is sold through the Company's US subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please visit: http://medicure.com/news.html.
Forward Looking Information Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements are based on the current assumptions, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions;
the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended May 31, 2011.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Medicure Inc.
Dawson Reimer
President & COO
888-435-2220
204-488-9823 (FAX)
info@medicure.com
www.medicure.com
MCUJ - Medicure Reports Third Quarter 2012 Financial Results
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ),
a specialty pharmaceutical company, today reported its third quarter 2012
financial results.
Third Quarter 2012 Highlights:
-- Recorded $4.4 million of revenue during the nine months ended February
29, 2012 compared to $2.9 million for the same period last year;
-- Net revenue from the sale of AGGRASTAT(R) finished product decreased
compared to third quarter last year to $660,000 and also decreased for
the nine months ended February 29, 2012 compared with the same period
last year to $2,510,000;
-- Net loss for the quarter was $0.4 million, compared to income of $1.1
million for the third quarter last year, a decrease primarily attributed
to lower foreign exchange gains and lower sales volumes, which were
partially offset by reduced financing expenses.
Financial Results
Net revenue from the sale of AGGRASTAT finished product for the three months
ended February 29, 2012 was $660,000 compared to $1,222,000 for the same quarter
last year. Net revenue from the sale of finished AGGRASTAT product for the nine
months ended February 29, 2012 decreased by $344,000 or 12% to $2,510,000 from
$2,854,000 for the same period last year. The decrease in revenues compared to
the same periods from the previous fiscal year is primarily attributable to an
overall decline in use of injectable antiplatelet drugs and normal fluctuations
in wholesale purchasing.
Net loss for the quarter was $0.4 million or $0.00 per share, compared to income
of $1.1 million or $0.01 per share in the third quarter a year ago. Net income
for the nine months ended February 29, 2012 was $24.2 million or $0.14 per
share, compared to $0.2 million or $0.00 per share for the same period a year
ago, primarily due to a $23.9 million non-cash gain relating to the settlement
of the Company's long-term debt in the first quarter, as well as a one-time sale
of unfinished product inventory during the first six months of fiscal 2012.
At February 29, 2012, the Company had cash totalling $1,670,151 compared to
$750,184 as of May 31, 2011. Cash flows from operating activities for the nine
months ended February 29, 2012 were $983,766, compared to $291,699 for the nine
months ended February 28, 2011.
Product Developments
The ongoing focus of the Company and its primary asset of interest is AGGRASTAT.
In parallel with its ongoing commitment to support and grow sales of the
product, the Company is in the process of developing a new regulatory, brand and
life cycle management strategy for AGGRASTAT. The objective of this strategy is
to expand AGGRASTAT's share of the US$360 million (US sales, calendar 2011)
glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor market and to advance a
contemporary treatment approach that increases the number of patients for whom
this treatment can be considered. GP llb/lla inhibitors are injectable
antiplatelet drugs used to treat acute coronary syndromes and related
conditions.
On January 30, 2012 the Company announced the launch of a new clinical trial
entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary
Intervention" (SAVI-PCI). The 600 patient study is designed to evaluate whether
patients receiving the investigational, High-Dose Bolus (HDB) regimen of
AGGRASTAT (25 mcg/kg bolus over 3 minutes) followed by an infusion of 0.15
mcg/kg/min for a shortened duration of 1 - 2 hours will have outcomes that are
similar, or "non-inferior," to patients receiving an 12 - 18 hour infusion of
Integrilin(R) (eptifibatide) (Merck & Co., Inc.) at its FDA approved dosing
regimen. The primary objective of SAVI-PCI is to demonstrate AGGRASTAT is
non-inferior to Integrilin with respect to the composite endpoint of death,
PCI-related myocardial infarction, urgent target vessel revascularization, or
major bleeding within 48 hours following PCI or hospital discharge. The
secondary objectives of this study include the assessment of safety as measured
by the incidence of major bleeding. The first patient is anticipated to be
enrolled in spring 2012. The Principal Investigator for the study is Steven V.
Manoukian, MD, Director of Cardiovascular Research at the Sarah Cannon Research
Institute (SCRI), Nashville, TN.
With the SAVI-PCI study, the investigators will explore whether AGGRASTAT HDB
plus a shortened infusion can reduce the risk of bleeding while maintaining
comparable effectiveness relative to the standard treatment regimen of
Integrilin. Other studies have indicated that shortening the infusion duration
of GP IIb/IIIa inhibitors can potentially lead to a reduction in bleeding
complications for patients undergoing PCI.
On January 23, 2012 the Company announced the addition of a site in India for
its ongoing Phase II Clinical Trial, TARDOXAL(TM) for the Management of
Neurological Disorders - Tardive Dyskinesia (TEND-TD). The Company anticipates
interim results from the study will be available in fall 2012. Tardive
Dyskinesia is a movement disorder that is a common side effect of the chronic
use of antipsychotic drugs. Currently there is no FDA approved drug for the
management of TD.
The Company's ability to continue in operation for the foreseeable future
remains dependent upon the effective execution of its business development and
strategic plans.
About Financial Statements and Transition to IFRS
In February 2008, the Canadian Accounting Standards Board (AcSB) confirmed that
the use of International Financial Reporting Standards (IFRS) would be required
for Canadian publicly accountable enterprises for interim and annual financial
statements effective for fiscal years beginning on or after January 1, 2011. The
Company implemented these standards on June 1, 2011. The unaudited condensed
consolidated interim financial statements for the nine months ended February 29,
2012 are prepared under IFRS. Further information on this transition,
comparisons to previous financial statements and the preparation of the
financial statements are described in the notes of the condensed consolidated
interim financial statements.
All amounts referenced herein are in Canadian dollars unless otherwise noted.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and
commercialization of novel small molecule therapeutics. The primary focus of the
Company and its subsidiaries is the marketing and distribution of AGGRASTAT(R)
(tirofiban HCl) for acute coronary syndromes in the United States, where it is
sold through the Company's US subsidiary, Medicure Pharma, Inc. For more
information on Medicure please visit www.medicure.com.
About Aggrastat
AGGRASTAT (tirofiban HCl), in combination with heparin, is indicated for the
treatment of acute coronary syndrome, including patients who are to be managed
medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT
has been shown to decrease the rate of a combined endpoint of death, new
myocardial infarction or refractory ischemia/repeat cardiac procedure. AGGRASTAT
has been studied in a setting that included aspirin and heparin.
Bleeding is the most common complication encountered during therapy with
AGGRASTAT. Administration of AGGRASTAT is associated with an increase in
bleeding events classified as both major and minor bleeding events by criteria
developed by the Thrombolysis in Myocardial Infarction Study group (TIMI). Most
major bleeding associated with AGGRASTAT occurs at the arterial access site for
cardiac catheterization. Fatal bleedings have been reported. AGGRASTAT should be
used with caution in patients with platelet count less than 150,000/mm3, in
patients with hemorrhagic retinopathy, and in chronic hemodialysis patients.
Because AGGRASTAT inhibits platelet aggregation, caution should be employed when
it is used with other drugs that affect hemostasis. The safety of AGGRASTAT when
used in combination with thrombolytic agents has not been established. During
therapy with AGGRASTAT, patients should be monitored for potential bleeding.
When bleeding cannot be controlled with pressure, infusion of AGGRASTAT and
heparin should be discontinued.
AGGRASTAT is a parenteral non-peptide, reversible GP IIb/IIIa receptor
antagonist that is marketed in the United States by Medicure Pharma, Inc.
Medicure does not promote unapproved use of AGGRASTAT. Please see the AGGRASTAT
Prescribing Information for approved indications, dosage regimens and safety
related information.
The AGGRASTAT dosing regimen and the treatment setting studied in the SAVI-PCI
study have not been approved by the FDA.
To be added to Medicure's e-mail list, please visit: http://medicure.com/news.html.
Forward Looking Information Statements contained in this press release that are
not statements of historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will", "estimates",
"continues", "anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to as
"forward-looking statements"). Forward-looking statements are based on the
current assumptions, estimates, analysis and opinions of management of the
Company made in light of its experience and its perception of trends, current
conditions and expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances. Inherent in
forward-looking statements are known and unknown risks, uncertainties and other
factors beyond the Company's ability to predict or control that may cause the
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements, and as such, readers are cautioned not to place
undue reliance on forward-looking statements.
Such risk factors include, among others, the Company's future product revenues,
stage of development, additional capital requirements, risks associated with the
completion and timing of clinical trials and obtaining regulatory approval to
market the Company's products, the ability to protect its intellectual property,
dependence upon collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in the industry.
Such statements are based on a number of assumptions which may prove to be
incorrect, including, but not limited to, assumptions about: general business
and economic conditions; the impact of changes in Canadian-US dollar and other
foreign exchange rates on the Company's revenues, costs and results; the timing
of the receipt of regulatory and governmental approvals for the Company's
research and development projects; the availability of financing for the
Company's commercial operations and/or research and development projects, or the
availability of financing on reasonable terms; results of current and future
clinical trials; the uncertainties associated with the acceptance and demand for
new products and market competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation to update
publicly or otherwise revise any forward-looking statements or the foregoing
list of factors, other than as may be required by applicable legislation.
Additional discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US Securities and
Exchange Commission, and in the "Risk Factors" section of its Form 20F for the
year ended May 31, 2011.
MCUJ - Short Volume for March 8th - 0%
MCUJ - I noticed it yesterday when I was looking for information on the site. It does look like they are getting things polished up.
Wow, has anyone taken a look at the Medicure website lately? BIG changes, it is a totally new look and feel... take a peek,
www.medicure.com
I don't know when it changed but I just noticed it today..
Cheers,
Sunpillar.
MCUJ - Short Volume for March 2nd - 0%
MCUJ - Short Volume for February 28th - 0%
MCUJ - Short Volume for February 24th - 0%
MCUJ - Short Volume for February 21st - 0%
MCUJ - Short Volume for February 17th - 0%
MCUJ - Short Volume for February 13th - 0%
MCUJ - Short Volume for February 9th - 28%
20120209|MCUJ|51575|0|181575|O
MCUJ this could breakout.. wouldn't take much imo
MCUJ - Short Volume for February 8th - 2%
20120208|MCUJ|10500|0|657232|O
HDSN drops the ask.
MCUJ - Smart strategy.
Will add on the dips if they allow any
MCUJ - Seeing some action on level 2's. Shakedown before another push into the ask?
MCUJ - Biotech Company In Focus After Strong Financials and Recent Positive Business Developments
MPH.V/MCUJ CURRENT PRICE: $0.04/$0.03
MPH.V/MCUJ TARGET PRICE: $1.10
MPH.V UPSIDE POTENTIAL: 2,650%
SHARES OUTSTANDING: 182,947,595
LAST QUARTER'S EPS: $0.01
February 6, 2012 - Toronto, ON - TSX News reports that Medicure Inc. (TSXV: MPH, OTCBB:MCUJ), a specialty pharmaceutical company, increased 33% on strong volume Monday thanks to rising investor sentiment over the company's recent strong financial performance, successful debt restructuring, the launch of the AGGRASTAT® Clinical Trial: SAVI-PCI and the positive update on the TEND-TD Phase II Clinical Trial.
Medicure's fundamentals are impeccable when compared to other biotechnology industry peers. MPH represents an unprecedented opportunity for investors to buy not only a company in the growing and speculative health care sector but one that makes money at a tremendous clip relative to its market cap today. Reviewing the TSX.com summary on MPH you immediately see that their EPS is 15 cents and their P/E ratio is only 0.2. That is not a mistake, their trailing four quarters of results show 15 cents per share of net income.
Much of that is due to their gain relating to the settlement of the Company's long-term debt. The creditors are so bullish about the business prospects for MPH that they were willing to take a short term hit with respect to the debt forgiveness in exchange for royalties on the company's AGGRASTAT® sales and an equity stake in the company. The CEO of Medicure Dr. Albert Friesen personally guaranteed a $5M loan from the Manitoba Development Corporation to support the Company's ongoing operations.
Although most of the net income over the past four quarters comes from the settlement of the loan, MPH reported a net income of $1.1M or 1 cent per share for the most recent quarter ended November 30, 2011 primarily from the sales of AGGRASTAT®. Referring to the company's SEDAR Filings for January 25, 2012, revenue was $2.25M and cost of goods sold $250K for a gross margin of nearly 90%. As the company continues to increase its sales of AGGRASTAT®, the profitability of MPH skyrockets because of its high gross margins.
There is every reason to believe that the company will continue to see strong growth in AGGRASTAT® sales. From the MD&A, "AGGRASTAT® is a GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS), including unstable angina and non-ST elevated myocardial infarction (NSTEMI)". As the American population ages and obesity continues to be rampant, AGGRASTAT® sales will continue to grow.
In addition to AGGRASTAT®, the company is in development of Tardoxal™, a naturally occurring, small molecule drug that is in development for a neurological condition known as Tardive Dyskinesia (TD). As a neurological disorder, TD has been linked with poor quality of life and increased medical morbidity and mortality. Successful trials of Tardoxal™ will lead to another revenue stream for MPH as it battles TD.
MPH has 182.9M shares outstanding with 2.3M stock options exercisable at 74 cents and 12.1M exercisable at 10 cents leading to a fully diluted amount of 197.3M shares with a cash injection of $2.9M upon exercise, equivalent to 1.5 cents of cash per share.
With the most recent quarter's net income being $1.1M, an absurdly conservative assumption of no growth in the business would lead to $4.4M in annual net income or 2.2 cents per fully diluted share. A P/E ratio of 50 would be very reasonable for a growing biotech company. This would lead to $1.10 per share stock price for MPH.
Medicure has excellent growth prospects and superior sales for a microcap biotech trading on the TSX Venture and OTCBB. Their revenue and net income beats many NASDAQ-listed biotech companies. They have a recently repaired balance sheet that had a debt settlement of $33M accepted by their creditor Birmingham Associates Ltd in exchange for sales royalties and an equity stake in the company. They have trials set in motion for their product pipelines to expand their market and a CEO with a significant personal guarantor stake on the $5M loan to the Manitoba Development Corporation. With these excellent current and future revenue prospects and heavy stakeholder involvement, the company is well-positioned to meet and exceed this $1.10 price target.
http://tsxnews.blogspot.com/2012/02/biotech-company-increases-in-price-due.html
MCUJ - Nice accumulation today. Looking forward to continued movement up.
Good Luck!
MCUJ - Short Volume for February 6th - 25%
20120206|MCUJ|158400|0|642000|O
MCUJ - Short Volume for February 7th - 2%
20120207|MCUJ|10000|0|419450|O
MCUJ - If both clinical trial programs are a success, $1.10 will be viewed as cheap.
MCUJ was above $1 in early 2008, I hope it can go back to that level in a year or two. Am I realistic?
MCUJ - Up 53% Target $1.10
http://tsxnews.blogspot.com/2012/02/biotech-company-increases-in-price-due.html
MCUJ - This is very positive! Price target of $1.10 would be huge!
MCUJ price target of $1.10
http://tsxnews.blogspot.com/2012/02/biotech-company-increases-in-price-due.html
MCUJ - Still holding a large position. Sold a little bit to diversify and grab a larger position in another stock I hold. Hoping this trends between $0.03 and $0.05 a bit longer. Would like to reestablish my original position and add more.
Good things coming to those buying at these levels, IMO.
MCUJ - I sold a small lot on Friday to free up some cash for a play that has potential to move just ahead of MCUJ. I pan on buying back my shares, even at a premium, and adding more to my position.
So those who may have gotten lucky on my small sell, may have plenty of opportunity to sell for a decent profit in the coming weeks.
Hope you don;t try to "scalp" me too much for my tickets back. LOL!
Still playing this to $0.10 short term and $0.40 long-term.
What makes you not want to get in? Just curious I really know little bits.
I bought some MCUJ this last week, small amount but went with the DD provided by STE. Any other quick DD is appreciated really busy might take a larger position down the road, especially since my other stock TD*I is going to move soon.
Thanks!
Can you please offer the ticker symbol for the stock you just bought into...either through private email or other method, thank you very much.
MCUJ - Heavy accumulation yesterday. Sold a small lot to grab shares of another play that could be equally as explosive as MCUJ. Hopefully will be buying that lot back, and then some, when that play, and a couple others run.
MCUJ is still my #1 potential runner for 2012. So I would like to add to my already solid position.
Yesterday's sale was a temporary offer to the accumulators. If they want any more of my holdings, they will need to get them above $0.10.
MCUJ - Short Volume for February 3rd - 0%
All gains practically erased. Company has a ways to go before establishing credibility.
Increase in price was none other than a short term day-trade. Need something solid from management in order to form a base in the share price.
MCUJ - Short Volume for February 2nd - 23%
20120202|MCUJ|50000|0|215000|O
MCUJ - Watching for EOD volume.
MCUJ - 600K on the bid at $0.029. Buying about to come in?
MA ready to cross also.
MCUJ - Very interesting. Looking forward to the next move up on accumulation and/or news.
I am tempted to reenter. I just have to figure out a good entry point before the next move.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1313
|
Created
|
10/18/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |